Physician profile
Jorge Martinez
NPI 1164475588
$4,458.16
in general payments reported to CMS, 2019-2025
36 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $717 · 2021: $1,021 · 2022: $990 · 2023: $332 · 2024: $107 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $818.14 | 2019-2023 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $422.52 | 2021-2025 | Glassia |
| Novo Nordisk INC | $378.07 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $339.08 | 2019-2022 | |
| Pfizer INC. | $334.78 | 2019-2023 | |
| Abbvie INC. | $322.28 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $225.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $197.87 | 2019-2023 | Vaxelis, Rotateq, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $151.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $147.98 | 2019-2023 | |
| Radius Health, INC. | $133.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.18 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $87.77 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $73.50 | 2020-2022 | |
| Allergan, INC. | $73.18 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $60.21 | 2021 | |
| Mannkind Corporation | $47.17 | 2023 | Afrezza |
| Biohaven Pharmaceutical Holding Company Ltd. | $45.65 | 2022 | |
| Medtronic, INC. | $44.94 | 2022-2023 | Minimed 770g |
| Glaxosmithkline, LLC. | $41.73 | 2019-2021 | |
| Sanofi Pasteur INC. | $36.10 | 2021-2023 | |
| Cranial Technologies, INC | $34.60 | 2020-2021 | |
| Horizon Therapeutics Plc | $34.54 | 2019-2022 | |
| Amarin Pharma, INC. | $31.66 | 2020 | |
| Dexcom, INC. | $31.27 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.94 | 2019-2020 | |
| Gilead Sciences, INC. | $29.65 | 2025 | |
| Abbott Laboratories | $24.12 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.19 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $21.91 | 2023 | Quviviq |
| Emd Serono, INC. | $18.74 | 2020 | |
| Valeritas, INC. | $17.89 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.65 | 2025 | Caplyta |
| Phadia US INC. | $17.37 | 2019 | |
| Astellas Pharma US INC | $17.03 | 2025 | Veozah |
| Insulet Corporation | $13.41 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.